Mesoblast signs ARDS therapy development deal with Novartis
Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of the former’s mesenchymal stromal cell…
Latest Deals
-
NovartisPartnership $1.3BN
-
BMSMergers & Acquisitions $13.1BN
-
RocheLicensing Agreement $308M
-
MerckMergers & Acquisitions $2.75BN
-
NovartisPartnership $1.3BN
-
BMSMergers & Acquisitions $13.1BN
-
RocheLicensing Agreement $308M
-
MerckMergers & Acquisitions $2.75BN
Merck acquires VelosBio: exploring the promise of ROR1 in cancer
Pharma giant Merck has entered into a definitive agreement to acquire oncology biotech VelosBio for $2.75bn in cash. The acquisition…
Latest News
View More
AstraZeneca-Oxford Covid-19 vaccine trial confirms strong immune response
AstraZeneca and Oxford University’s late-stage trial has showed that their Covid-19 vaccine candidate, ChAdOx1 nCoV-19, induced a strong immune response in older adults. The study…
Johnson & Johnson gets approval for Phase III Covid-19 vaccine trial in Spain
The Spanish Agency for Medicines and Health Products (AEMPS) has authorised the initiation of Phase III trials of Johnson & Johnson (J&J) unit Janssen’s Covid-19…
FDA to review Samsung Bioepis and Biogen’s biosimilar SB11
The US Food and Drug Administration (FDA) has accepted Samsung Bioepis and Biogen’s biologics licence application to review the use…
Merck acquires VelosBio: exploring the promise of ROR1 in cancer
Pharma giant Merck has entered into a definitive agreement to acquire oncology biotech VelosBio for $2.75bn in cash. The acquisition…
Pfizer, BioNTech’s final Covid-19 vaccine study shows 95% efficacy
Pfizer and BioNTech have concluded the Phase III study of their mRNA-based Covid-19 vaccine candidate, BNT162b2, which showed 95% efficacy…
Sinovac’s CoronaVac triggers quick immune response in Covid-19 trial
Sinovac Biotech has reported the preliminary results from Phase I/II trial that showed its experimental Covid-19 vaccine, CoronaVac, triggered a…
Company A-Z
View More
SIRION Biotech
Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development
Latest Content
View More
Araris raises CHF15.2m to support its next-gen ADCs
Switzerland-based Araris Biotech has raised CHF15.2m ($16.6m) in a seed financing round. The round was led by Pureos Bioventures and…
CStone and LegoChem to jointly develop novel antibody drug conjugate
CStone Pharmaceuticals and LegoChem Biosciences (LCB) have signed a licensing agreement for the development and commercialisation of a potential antibody-drug…
SenseAnywhere to Monitor Covid-19 Vaccines in Europe During Storage and Transportation
SenseAnywhere is specialised in fully automated temperature monitoring for the Pharmaceutical Industry for years already. Soon our AiroSensors, in combination…
Peltier-cooled Incubator IPPeco
Memmert's Peltier-cooled incubator IPPeco sets eco-standards for cultivation below room temperature. The product has unmatched energy efficiency, best values for…
Constant Climate Chamber HPPeco
Memmert's climate chambers offer maximum energy efficiency in continuous operation - customised for stability studies according to ICH guidelines. This…
CO2 Incubator ICOmed
Those who can control the temperature with the highest precision can also redefine precision time and time again. The control…